Abstract
Regenerative medicine is an emerging clinical discipline in which cell-based therapies are used to restore the functions of damaged or defective tissues and organs. Along with the well-established use of cells derived from bone marrow or pancreatic islets, novel approaches of cell therapy have recently emerged that appear particularly promising; that is, those using cell-based vaccines and stem cells. This review focuses on the recent developments of these experimental therapeutic approaches and their drawbacks, with specific focus on dendritic cell vaccines in tumours and mesoangioblasts in muscular dystrophies. The authors discuss how the unique properties of a gaseous messenger, NO, may be exploited to overcome some of the draw-backs of these cell-based approaches in combined therapies based on NO-releasing drugs and cell delivery.
Original language | English |
---|---|
Pages (from-to) | 33-43 |
Number of pages | 11 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 16 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2007 |
Keywords
- Cell-based vaccines
- cGMP
- Dendritic cells
- Lymphocytes
- Mesoangioblasts
- Muscular dystrophy
- NO-releasing drugs
- Sphingolipids
- Stem cells
ASJC Scopus subject areas
- Pharmacology